FDA: FDA updates Sotrovimab emergency use authorization

FDA updates Sotrovimab emergency use authorization

FDA (News)

FDA, FDA updates Sotrovimab emergency use authorization, (News)

Apr 2022 Source PDF

FDA has revoked sotrovimab's authorization in all regions due to predicted low efficacy with BA.2, and BA.2 exceeding 50% prevalence in all regions.

Important missing comments or errors? Let us know.

This study includes sotrovimab and tixagevimab/cilgavimab.

FDA et al., 5 Apr 2022, preprint, 1 author.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Sotrovimab All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit